Turning Point Therapeutics, Inc. Common Stock
TPTX
TPTX was delisted on the 16th of August, 2022.
193 hedge funds and large institutions have $5.28B invested in Turning Point Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 93 increasing their positions, 54 reducing their positions, and 10 closing their positions.
270% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 10
118% more call options, than puts
Call options by funds: $3.69M | Put options by funds: $1.69M
72% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 54
53% more capital invested
Capital invested by funds: $3.45B → $5.28B (+$1.82B)
16% more funds holding
Funds holding: 166 → 193 (+27)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$65.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$61.7M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$51.7M |
| 4 |
BlackRock
New York
|
+$49.8M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$28.8M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$14.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$12M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$10.6M |
| 5 |
SCM
Suvretta Capital Management
New York
|
-$6.93M |
TPTX Hedge Fund Activity: Q4 2020 in Review
193 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q4 2020, worth a combined $5.28B — up 53% from $3.45B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new TPTX positions and 10 closed out — a net gain of 27 holders — while 93 added to existing stakes and 54 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $65.1M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $28.8M sold.
- 193 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q4 2020, up from 166 in Q3 2020.
- Funds reported $5.28B of Turning Point Therapeutics, Inc. Common Stock stock for Q4 2020, up 53% quarter-over-quarter.
- 37 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q4 2020 and 10 closed out, a net change of +27 holders.
- The largest Turning Point Therapeutics, Inc. Common Stock buyer in Q4 2020 was T. Rowe Price Associates, an estimated $65.1M added.
- The largest Turning Point Therapeutics, Inc. Common Stock seller in Q4 2020 was Perceptive Advisors, an estimated $28.8M sold.
Based on aggregated 13F filings for Q4 2020.